The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 Billion by 2021 from USD 1.35 Billion in 2016, at a CAGR of 16.4% from 2016 to 2021. The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.
The market in this report is segmented on the basis of product, method, application, end user, and region. Based on product, the market is segmented into consumables and instruments. The consumable segment is further divided into assay kits & reagents and disposables. The instruments segment is divided into ultrasound device, NGS systems, PCR instruments, microarrays, and other instruments. In 2016, the consumables segment accounted for the largest share of the market. The high growth in this segment is attributed to the repeated requirements of consumables as compared to instruments in NIPT.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=145607690
Based on method, the market is further divided into ultrasound detection, biochemical screening tests, fetal cells in maternal blood tests, and cell-free DNA in maternal plasma tests. In 2016, the ultrasound detection accounted for the largest share of the market. However, the cell-free DNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period. This is mainly attributed to the increasing demand for cf-DNA based techniques in NIPT testing and rising government initiatives to provide prenatal services.
Based on application, the market is divided into Trisomy, microdeletion syndrome, and other applications. Trisomy forms the largest and fastest-growing application segment of the global market. This is mainly attributed to the rising incidence of chromosomal abnormalities with increasing maternal age.
Based on end user, the market is segmented into diagnostic laboratories and hospitals. In 2016, the diagnostic laboratories segment accounted for the largest share of the market. Growth in this end-user segment can be attributed to the rising incidence of chromosomal abnormalities and increasing initiatives by companies to provide advanced products in NIPT to diagnostic laboratories.
The global market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The market in Asia is expected to grow at the highest CAGR during the forecast period. Factors such as increasing awareness programs, high incidence of genetic disorders, increasing healthcare infrastructure, and rising disposable income are some of the factors contributing to the growth of the market in Asia.
Key market players are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).